Innate immune signaling pathways in human monocytes

Innate immune signaling pathways in human monocytes represent a complex network of biochemical cascades that allow these myeloid cells to detect and respond to pathogens and cellular stress. These pathways are initiated by pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and NOD-like receptors (NLRs), which recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) (Source: Janeway's Immunobiology, 9th ed.). Upon activation, these receptors trigger downstream signaling through adaptors like MyD88 or TRIF, leading to the activation of transcription factors such as NF-κB and Interferon Regulatory Factors (IRFs) (Source: Nature Reviews Immunology, 2011; PMID: 21946614). This process results in the production of pro-inflammatory cytokines, chemokines, and interferons that coordinate the host defense. Dysregulation of these pathways is a hallmark of various inflammatory and autoimmune disorders, making specific components within the pathways high-value therapeutic targets (Source: StatPearls, 2023; NBK482340). While the pathways themselves are not a single target, drugs like JAK inhibitors and monoclonal antibodies against cytokines are used to modulate their activity in clinical settings (Source: Nature Reviews Drug Discovery, 2017; PMID: 28473515). Monocytes also play a critical role in the transition from innate to adaptive immunity by presenting antigens and providing costimulatory signals. Therapeutic intervention in these pathways requires a balance between reducing harmful inflammation and maintaining sufficient immune surveillance to prevent infections.

Other names

Monocyte innate immune responseInnate immune signaling in monocytesMonocyte pattern recognition receptor signaling

Drugs targeting these pathways typically function by blocking the binding of pro-inflammatory cytokines to their receptors or by inhibiting intracellular signaling enzymes like Janus kinases (JAKs), thereby preventing the transcription of inflammatory genes (Source: Nature Reviews Drug Discovery, 2017; PMID: 28473515).